ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical firm targeted on creating and commercializing merchandise for the remedy of central nervous system (CNS) illnesses, in the present day introduced that the Company expects to report monetary and business outcomes for the third quarter of 2022 after the market closes on Tuesday, November 8, 2022.
Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a convention name to current the third quarter 2022 monetary and business outcomes on Tuesday, November 8, 2022, at 4:30 p.m. ET. Following administration’s ready remarks and dialogue of business outcomes, the decision might be open for questions.
A reside webcast might be accessible within the Events & Presentations part of the Company’s Investor Relations web site www.supernus.com/buyers.
Participants may additionally pre-register any time earlier than the decision right here. Once registration is accomplished, contributors might be offered a dial-in quantity with a personalised convention code to entry the decision. Please dial in quarter-hour prior to the beginning time.
Following the reside name, a replay might be obtainable on the Company’s web site, www.supernus.com/buyers. The webcast might be obtainable on the Company’s web site for 60 days following the reside name.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical firm targeted on creating and commercializing merchandise for the remedy of central nervous system (CNS) illnesses.
Our various neuroscience portfolio contains authorized remedies for epilepsy, migraine, ADHD, hypomobility in Parkinson’s illness (PD), cervical dystonia, power sialorrhea, dyskinesia in PD sufferers receiving levodopa-based remedy, and drug-induced extrapyramidal reactions in grownup sufferers. We are creating a broad vary of novel CNS product candidates together with new potential remedies for hypomobility in PD, epilepsy, melancholy, and different CNS problems.
For extra info, please go to www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Tim Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Westwicke
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
